Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2021; 13(12): 2113-2127
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2113
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2113
Use of oral vancomycin in children with autoimmune liver disease: A single centre experience
Angelo Di Giorgio, Anna Tulone, Emanuele Nicastro, Lorenzo Norsa, Lorenzo D'Antiga, Pediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII , Bergamo 24127, Italy
Aurelio Sonzogni, Liver Pathology, Hospital Papa Giovanni XXIII, Bergamo 24127, Italy
Author contributions: Di Giorgio A, Tulone A drafted the paper; Di Giorgio A wrote the paper; Tulone A collected data; Nicastro E and Sonzogni A contributed to the conception analysis; Nicastro E, Norsa L, Sonzogni A, and D’Antiga L contributed to the interpretation of data; Norsa L performed the research; D’Antiga L supervised the study; and all authors approved the submission of this version of the manuscript and takes full responsibility for the manuscript contents.
Institutional review board statement: At our centre (tertiary referral centre for liver transplantation), no approval by local ethical committee is required for retrospective anonymised study which includes only patients from our centre.
Informed consent statement: The informed consent statement was waived.
Conflict-of-interest statement: There are no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Angelo Di Giorgio, MD, PhD, Pediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII , Piazza Oms 1, Bergamo 24127, Italy. adigiorgio@asst-pg23.it
Received: May 27, 2021
Peer-review started: May 27, 2021
First decision: July 6, 2021
Revised: July 7, 2021
Accepted: November 25, 2021
Article in press: November 25, 2021
Published online: December 27, 2021
Processing time: 213 Days and 16.9 Hours
Peer-review started: May 27, 2021
First decision: July 6, 2021
Revised: July 7, 2021
Accepted: November 25, 2021
Article in press: November 25, 2021
Published online: December 27, 2021
Processing time: 213 Days and 16.9 Hours
Core Tip
Core Tip: Experience with oral vancomycin in children with autoimmune liver disease (AILD) is limited. We enrolled 75 children [median age 10.5 years (5.6-13.4)], 54 with autoimmune hepatitis and 21 with autoimmune sclerosing cholangitis; 63/75 achieved remission by standard immunosuppressive therapy (IS), whereas 12/75 (16%) required oral vancomycin treatment (OVT). In 6/12 patients (50%) the response was complete, whereas it was partial in 2/12 (17%), and absent in 4/12 (33%). Overall OVT increased the remission rate of the whole group of AILD patients from 81% to 92%. OVT may represent a valuable treatment option in children with AILD who do not respond to standard IS.